Miach Orthopaedics Raises $20 Million in Series B Extension
Miach Orthopaedics, Inc. , a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced closing of a $20 million Series B extension financing round.
- Miach Orthopaedics, Inc. , a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced closing of a $20 million Series B extension financing round.
- The BEAR Implant is the first disruptive technology in ACL tear treatment in more than 30 years.
- It is a paradigm shift from the current standard of care – reconstruction that replaces the ACL with a graft.
- “This Series B extension diversifies Miach’s investor group and provides additional resources to further market growth in the U.S. toward the goal of establishing the BEAR Implant as a new standard of care for ACL tears.”
For more information about the BEAR Implant, visit miachortho.com .